{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:14:29Z","timestamp":1792620869629,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006353","name":"Charles Stark Draper Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.semnephrol.2023.151479","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T15:21:09Z","timestamp":1704727269000},"page":"151479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Immunologic Effects of Heparin Associated With Hemodialysis: Focus on Heparin-Induced Thrombocytopenia"],"prefix":"10.1016","volume":"43","author":[{"given":"Theodore E.","family":"Warkentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semnephrol.2023.151479_bib0001","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0272-6386(96)90134-1","article-title":"Heparin-induced thrombocytopenia in hemodialysis patients","volume":"28","author":"Yamamoto","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2023.151479_bib0002","series-title":"Heparin-Induced Thrombocytopenia","first-page":"520","article-title":"Hemodialysis in heparin-induced thrombocytopenia","author":"Fischer","year":"2013"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151479_bib0003","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMp068309","article-title":"Drug-induced immune-mediated thrombocytopenia\u2014from purpura to thrombosis","volume":"356","author":"Warkentin","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151479_bib0004","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1365-2141.2003.04334.x","article-title":"Heparin-induced thrombocytopenia: Pathogenesis and management","volume":"121","author":"Warkentin","year":"2003","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151479_bib0005","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A 14-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151479_bib0006","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1055\/s-0040-1712957","article-title":"Comparative analysis of a French prospective series of 144 patients with heparin-induced thrombocytopenia (FRIGTIH) and the literature","volume":"120","author":"Gruel","year":"2020","journal-title":"Thromb Haemost"},{"issue":"20","key":"10.1016\/j.semnephrol.2023.151479_bib0007","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2023.151479_bib0008","first-page":"S92","article-title":"HITlights: A career perspective on heparin-induced thrombocytopenia","volume":"87","author":"Warkentin","year":"2012","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151479_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0037-1614206","article-title":"Heparin-induced thrombocytopenia: Towards consensus","volume":"79","author":"Warkentin","year":"1998","journal-title":"Thromb Haemost"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2023.151479_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/ijlh.12993","article-title":"Laboratory diagnosis of heparin-induced thrombocytopenia","volume":"41","author":"Warkentin","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"17","key":"10.1016\/j.semnephrol.2023.151479_bib0011","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJM200104263441704","article-title":"Temporal aspects of heparin-induced thrombocytopenia","volume":"344","author":"Warkentin","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151479_bib0012","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1378\/chest.122.1.37","article-title":"Heparin-induced thrombocytopenia: Temporal pattern of thrombocytopenia in relation to initial use of reexposure to heparin","volume":"122","author":"Lubenow","year":"2002","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151479_bib0013","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1538-7836.2009.03735.x","article-title":"Anti-PF4\/heparin antibody formation post-orthopedic surgery thromboprophylaxis: The role of non-drug risk factors and evidence for a stoichiometry-based model of immunization","volume":"8","author":"Warkentin","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151479_bib0014","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1111\/jth.14897","article-title":"Maximum 24-hour platelet count fall rate as a predictor of heparin-induced thrombocytopenia","volume":"18","author":"Lefler","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151479_bib0015","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/jth.15826","article-title":"Temporal presentations of heparin-induced thrombocytopenia following cardiac surgery: A single-centre, retrospective cohort study","volume":"20","author":"Warkentin","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151479_bib0016","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1160\/TH12-11-0865","article-title":"Adrenal haemorrhage due to heparin-induced thrombocytopenia","volume":"109","author":"Ketha","year":"2013","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151479_bib0017","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJM200303133481120","article-title":"Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin","volume":"348","author":"Warkentin","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151479_bib0018","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1161\/STROKEAHA.121.036824","article-title":"Cerebral venous thrombosis in patients with heparin-induced thrombocytopenia: A systematic review","volume":"53","author":"Aguiar de Sousa","year":"2022","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151479_bib0019","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1365-2141.1996.d01-1481.x","article-title":"Heparin-induced skin lesions","volume":"92","author":"Warkentin","year":"1996","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151479_bib0020","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ajh.24018","article-title":"Non-injection site necrotic skin lesions complicating postoperative heparin thromboprophylaxis","volume":"90","author":"Tassava","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151479_bib0021","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000188232","article-title":"Severe skin necrosis associated with heparin in hemodialysis","volume":"68","author":"Leblanc","year":"1994","journal-title":"Nephron"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151479_bib0022","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2002-05-1448","article-title":"Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia","volume":"101","author":"Hong","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151479_bib0023","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/0003-4819-127-9-199711010-00005","article-title":"The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia","volume":"127","author":"Warkentin","year":"1997","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151479_bib0024","doi-asserted-by":"crossref","first-page":"omab002","DOI":"10.1093\/omcr\/omab002","article-title":"Heparin-induced thrombocytopenia during IgA vasculitis: A case report","volume":"2021","author":"Yamasaki","year":"2021","journal-title":"Oxf Med Case Reports"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151479_bib0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.transproceed.2021.11.012","article-title":"Case report: Heparin-induced thrombocytopenia treated with plasmapheresis before living-donor kidney transplantation","volume":"54","author":"Motokazu","year":"2022","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151479_bib0026","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/14740330902778180","article-title":"Heparin-induced anaphylactic and anaphylactoid reactions: Two distinct but overlapping syndromes","volume":"8","author":"Warkentin","year":"2009","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151479_bib0027","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5414\/CNP63236","article-title":"Thrombocytopenia and anaphylaxis secondary to heparin in a hemodialysis patient","volume":"63","author":"Tejedor Alonso","year":"2005","journal-title":"Clin Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151479_bib0028","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.thromres.2011.10.012","article-title":"Clinical evaluation of acute systemic reaction and detection of IgG antibodies against PF4\/heparin complexes in hemodialysis patients","volume":"129","author":"Matsuo","year":"2012","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151479_bib0029","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.thromres.2011.11.004","article-title":"Hemodialysis-associated acute systemic reactions and heparin-induced thrombocytopenia","volume":"129","author":"Warkentin","year":"2012","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151479_bib0030","doi-asserted-by":"crossref","first-page":"c143","DOI":"10.1159\/000094959","article-title":"Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: Safety of resuming heparin after disappearance of HIT antibodies","volume":"104","author":"Hartman","year":"2006","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151479_bib0031","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1398-9995.2006.00982.x","article-title":"Haemodialysis-associated anaphylactic and anaphylactoid reactions","volume":"61","author":"Ebo","year":"2006","journal-title":"Allergy"},{"issue":"9029","key":"10.1016\/j.semnephrol.2023.151479_bib0032","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0140-6736(05)65684-X","article-title":"Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis","volume":"348","author":"Greinacher","year":"1996","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151479_bib0033","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000045044","article-title":"Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients","volume":"79","author":"Sitter","year":"1998","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151479_bib0034","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ajh.10032","article-title":"Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis","volume":"69","author":"O'Shea","year":"2002","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.semnephrol.2023.151479_bib0035","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151479_bib0036","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk of heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151479_bib0037","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12882-017-0596-4","article-title":"Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: A systematic review and meta-analysis","volume":"18","author":"Lazrak","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151479_bib0038","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-2369-15-104","article-title":"Avoidance of systemic anticoagulation during intermittent haemodialysis with heparin-grafted polyacrilonitrile membrane and citrate-enriched dialysate: A retrospective cohort study","volume":"15","author":"Fran\u00e7ois","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151479_bib0039","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1745-6215-14-163","volume":"14","author":"Rossignol","year":"2013","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151479_bib0040","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/ki.2014.225","article-title":"Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis","volume":"86","author":"Laville","year":"2014","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151479_bib0041","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/ndt\/gfw461","article-title":"A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: Results of the CiTED study","volume":"32","author":"Meijers","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151479_bib0042","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1053\/j.ajkd.2021.04.004","article-title":"Dialyzer performance during hemodialysis without systemic anticoagulation using a heparin-grafted dialyzer combined with a citrate-enriched dialysate: Results of the randomized crossover noninferiority EvoCit study","volume":"79","author":"Fran\u00e7ois","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151479_bib0043","first-page":"298","article-title":"Treatment of severe dialysis reactions with the AN69-ST membrane: Biocompatibility does matter","volume":"3","author":"Coentr\u00e3o","year":"2010","journal-title":"NDT Plus"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151479_bib0044","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2009-07-231506","article-title":"The severity of trauma determines the immune response to PF4\/heparin and the frequency of heparin-induced thrombocytopenia","volume":"115","author":"Lubenow","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151479_bib0045","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.nefroe.2018.02.011","article-title":"Haemodialysis-related-heparin-induced thrombocytopenia: Case series and literature review","volume":"38","author":"Gameiro","year":"2018","journal-title":"Nefrologia (Engl Ed)"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151479_bib0046","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1093\/ndt\/12.12.2750","article-title":"Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia","volume":"12","author":"Tholl","year":"1997","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151479_bib0047","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1160\/TH17-03-0212","article-title":"Platelet count recovery and seroreversion in immune HIT despite continuation of heparin: Further observations and literature review","volume":"117","author":"Shih","year":"2017","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151479_bib0048","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0042-1758818","article-title":"Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: A narrative review","volume":"49","author":"Warkentin","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151479_bib0049","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.thromres.2007.11.007","article-title":"Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings","volume":"122","author":"Greinacher","year":"2008","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151479_bib0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.lab.2005.08.003","article-title":"Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?","volume":"146","author":"Warkentin","year":"2005","journal-title":"J Lab Clin Med"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151479_bib0051","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1538-7836.2007.02617.x","article-title":"Heparin-induced thrombocytopenia: A prospective study on the incidence, platelet-activating capacity and clinical significance of anti-PF4\/heparin antibodies of the IgG, IgM, and IgA classes","volume":"5","author":"Greinacher","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.semnephrol.2023.151479_bib0052","series-title":"Heparin-Induced Thrombocytopenia","first-page":"209","article-title":"Platelet and leukocyte Fc\u03b3 receptors in heparin-induced thrombocytopenia","author":"Denomme","year":"2013"},{"issue":"suppl 2","key":"10.1016\/j.semnephrol.2023.151479_bib0053","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ijlh.14075","article-title":"Platelet factor 4 triggers thrombo-inflammation by bridging innate and adaptive immunity","volume":"45","author":"Greinacher","year":"2023","journal-title":"Int J Lab Hematol"},{"issue":"21","key":"10.1016\/j.semnephrol.2023.151479_bib0054","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.3390\/jcm12216921","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"12","author":"Warkentin","year":"2023","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151479_bib0055","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-135-7-200110020-00009","article-title":"Delayed-onset heparin-induced thrombocytopenia and thrombosis","volume":"135","author":"Warkentin","year":"2001","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151479_bib0056","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.chest.2017.03.050","article-title":"IVIG for treatment of severe refractory heparin-induced thrombocytopenia","volume":"152","author":"Padmanabhan","year":"2017","journal-title":"Chest"},{"issue":"14","key":"10.1016\/j.semnephrol.2023.151479_bib0057","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2017-06-788679","article-title":"Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma","volume":"130","author":"Mian","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151479_bib0058","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","article-title":"High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: A review","volume":"12","author":"Warkentin","year":"2019","journal-title":"Exp Rev Hematol"},{"issue":"22","key":"10.1016\/j.semnephrol.2023.151479_bib0059","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151479_bib0060","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa2107051","article-title":"Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia","volume":"385","author":"Bourguignon","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151479_bib0061","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ana.26431","article-title":"Management of cerebral venous thrombosis due to adenoviral COVID-19 vaccination","volume":"92","author":"Scutelnic","year":"2022","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151479_bib0062","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1538-7836.2010.03880.x","article-title":"Non-necrotizing heparin-induced skin lesions and the 4T's score","volume":"8","author":"Warkentin","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.semnephrol.2023.151479_bib0063","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40164-018-0115-8","article-title":"Temporality of heparin-induced antibodies: A retrospective study in outpatients undergoing hemodialysis on unfractionated heparin","volume":"7","author":"Maharaj","year":"2018","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151479_bib0064","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: Heparin-induced thrombocytopenia","volume":"22","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.semnephrol.2023.151479_bib0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/asheducation-2011.1.143","article-title":"How I diagnose and manage HIT","volume":"2011","author":"Warkentin","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151479_bib0066","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/j.thromres.2009.10.008","article-title":"A review of 122 published outcomes of danaparoid anticoagulation for intermittent hemodialysis","volume":"125","author":"Magnani","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.semnephrol.2023.151479_bib0067","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.thromres.2019.06.008","article-title":"Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia\u2014need for a higher than recommended weight-based dosing","volume":"180","author":"Castelino","year":"2019","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151479_bib0068","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/aor.12002","article-title":"Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: Dose-finding study and safety evaluation","volume":"37","author":"Mahieu","year":"2013","journal-title":"Artif Organs"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151479_bib0069","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40360-023-00643-4","article-title":"Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: A retrospective review of institutional protocol","volume":"24","author":"Ghaziri","year":"2023","journal-title":"BMC Pharmacol Toxicol."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151479_bib0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1517\/14740338.2013.823946","article-title":"Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls","volume":"13","author":"Warkentin","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151479_bib0071","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0049-3848(99)00029-8","article-title":"Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C","volume":"95","author":"Linder","year":"1999","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151479_bib0072","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0049-3848(01)00392-9","article-title":"Effect of different types of thrombin inhibitors on thrombin\/thrombomodulin modulated activation of protein C in vitro","volume":"104","author":"Mattsson","year":"2001","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151479_bib0073","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00001721-200302000-00004","article-title":"Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors","volume":"14","author":"Linder","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151479_bib0074","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ijlh.13126","article-title":"Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays","volume":"42","author":"Aungraheeta","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151479_bib0075","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/jth.12591","article-title":"Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo","volume":"12","author":"Perzborn","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151479_bib0076","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.hoc.2010.05.009","article-title":"Agents for the treatment of heparin-induced thrombocytopenia","volume":"24","author":"Warkentin","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151479_bib0077","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ccc.2011.08.001","article-title":"Heparin-induced thrombocytopenia in critically ill patients","volume":"27","author":"Warkentin","year":"2011","journal-title":"Crit Care Clin"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151479_bib0078","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1111\/trf.15263","article-title":"Autoimmune heparin-induced thrombocytopenia and venous limb gangrene following aortic dissection repair: In vitro and in vivo effects of intravenous immunoglobulin","volume":"59","author":"Arcinas","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.semnephrol.2023.151479_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151476","article-title":"How to ensure Patency of the extracorporeal circuit in hemodialysis: global perspectives","author":"Santos","year":"2023","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151479_bib0080","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.actbio.2019.06.021","article-title":"The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem","volume":"94","author":"Jaffer","year":"2019","journal-title":"Acta Biomater"},{"key":"10.1016\/j.semnephrol.2023.151479_bib0081","unstructured":"Fran\u00e7ois K, Orlando C, Jochmans K, et al. Heparin-grafted dialyzer use is safe in case of heparin-induced thrombocytopenia. Paper presented at: Belgian Society of Nephrology Annual Meeting; May 27, 2021. Accessed January 6, 2024. http:\/\/www.bvn-sbn.be\/downloads\/ABSTRACT%20BOOK%20ANNUAL%20MEETING%202021.pdf"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151479_bib0082","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.avsg.2011.12.011","article-title":"Outcomes after heparin-induced thrombocytopenia in patients with Propaten vascular grafts","volume":"26","author":"Kasirajan","year":"2012","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.semnephrol.2023.151479_bib0083","series-title":"Heparin-Induced Thrombocytopenia","first-page":"573","article-title":"Heparin-coated intravascular devices and heparin-induced thrombocytopenia","author":"Warkentin","year":"2013"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151479_bib0084","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1258\/vasc.2011.cr0280","article-title":"Heparin-induced thrombocytopenia in the presence of a heparin-bonded bypass graft","volume":"19","author":"Wheatcroft","year":"2011","journal-title":"Vascular."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151479_bib0085","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/blood-2016-01-635003","article-title":"How I treat patients with a history of heparin-induced thrombocytopenia","volume":"128","author":"Warkentin","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151479_bib0086","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1538-7836.2009.03734.x","article-title":"Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia","volume":"8","author":"Wanaka","year":"2010","journal-title":"J Thromb Haemost"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:20:37Z","timestamp":1762280437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523001894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0270929523001894"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151479","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunologic Effects of Heparin Associated With Hemodialysis: Focus on Heparin-Induced Thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151479"}}